Kodiak Sciences (NASDAQ:KOD) Stock Gets Price Target Increase from JPMorgan Chase & Co.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) had its price target hoisted by JPMorgan Chase & Co. from $124.00 to $128.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 31.73% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the stock. UBS Group upped their price target on shares of Kodiak Sciences from $120.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, November 13th. Lifesci Capital increased their price objective on shares of Kodiak Sciences from $85.00 to $145.00 and gave the company an “outperform” rating in a research report on Monday, September 28th. The Goldman Sachs Group started coverage on shares of Kodiak Sciences in a research note on Wednesday, September 30th. They set a “neutral” rating and a $103.00 price objective for the company. Weiss Ratings lowered shares of Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $112.00 target price on shares of Kodiak Sciences in a report on Monday, September 28th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Kodiak Sciences currently has an average rating of “Moderate Buy” and an average price target of $117.86.

Check Out Our Latest Stock Analysis on Kodiak Sciences

Kodiak Sciences Trading Down 0.7%

Kodiak Sciences stock opened at $97.17 on Thursday. The business’s fifty day simple moving average is $83.13 and its two-hundred day simple moving average is $47.59. Kodiak Sciences has a 12 month low of $19.25 and a 12 month high of $112.79. The company has a market capitalization of $6.35 billion, a price-to-earnings ratio of -23.82 and a beta of 2.02.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.01. On average, equities research analysts predict that Kodiak Sciences will post -4.05 EPS for the current year.

Insider Transactions at Kodiak Sciences

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker acquired 807,840 shares of the stock in a transaction that occurred on Monday, September 28th. The shares were acquired at an average cost of $72.57 per share, with a total value of $58,624,948.80. Following the transaction, the director owned 19,121,134 shares of the company’s stock, valued at $1,387,620,694.38. The trade was a 4.41% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders purchased 2,188,845 shares of company stock valued at $181,326,862. Corporate insiders own 44.40% of the company’s stock.

Institutional Trading of Kodiak Sciences

A number of institutional investors and hedge funds have recently modified their holdings of KOD. Baker BROS. Advisors LP raised its holdings in shares of Kodiak Sciences by 9.7% during the third quarter. Baker BROS. Advisors LP now owns 21,860,941 shares of the company’s stock valued at $2,072,417,000 after purchasing an additional 1,941,755 shares during the last quarter. BlackRock Inc. purchased a new stake in Kodiak Sciences in the second quarter worth approximately $161,113,000. Jupiter Topco LLC purchased a new stake in Kodiak Sciences in the second quarter worth approximately $59,507,000. Janus Henderson Group PLC boosted its holdings in Kodiak Sciences by 32.5% in the first quarter. Janus Henderson Group PLC now owns 1,325,457 shares of the company’s stock worth $50,540,000 after purchasing an additional 325,457 shares during the last quarter. Finally, ICONIQ Capital LLC purchased a new stake in Kodiak Sciences in the second quarter worth approximately $49,345,000. Institutional investors own 89.06% of the company’s stock.

About Kodiak Sciences

(Get Free Report)

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.

Further Reading

Analyst Recommendations for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.